Skip to main content

Day: October 7, 2021

Colliers to Acquire Best in Class Italian Investment Management Business

Written by Customer Service on . Posted in Mergers And Acquisitions.

Further Expands Colliers Global Investors platform in EuropeChris McLernon, CEO, EMEA, Colliers and Ofer Arbib, founder and CEO, Antirion SGR S.p.A.,COLLIERS TO ACQUIRE BEST IN CLASS ITALIAN INVESTMENT MANAGEMENT BUSINESSTORONTO and MILAN, Italy, Oct. 07, 2021 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), announced today it has entered into an agreement to acquire a controlling interest in Antirion SGR S.p.A., one of the largest real estate investment management firms in Italy with assets throughout Western Europe. Ofer Arbib, founder and CEO and his team will continue to lead the organization and will retain a significant equity interest in the firm going forward under Colliers’ unique partnership model. The firm will be rebranded...

Continue reading

Colliers to acquire best in class Italian investment management business

Written by Customer Service on . Posted in Mergers And Acquisitions.

Further expands Colliers Global Investors’ platform in Europe TORONTO and MILAN, Italy, Oct. 07, 2021 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), announced today it has entered into an agreement to acquire a controlling interest in Antirion SGR S.p.A., one of the largest real estate investment management firms in Italy with assets throughout Western Europe. Ofer Arbib, founder and CEO and his team will continue to lead the organization and will retain a significant equity interest in the firm going forward under Colliers’ unique partnership model. The firm will be rebranded as Colliers Global Investors shortly after closing. This investment further expands Colliers Global Investors’ growing platform in Europe and leverages its benefits for existing...

Continue reading

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates Expands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineering and oncologySOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) announced today that ALX Oncology has acquired ScalmiBio. ALX Oncology further expands its pipeline with plans to develop new anti-cancer drug candidates based on ScalmiBio’s platform; these new molecules will be designed to address unmet cancer patient needs as stand-alone therapeutics and in combination with ALX Oncology’s lead product candidate,...

Continue reading

Rapid Spread of COVID-19 across the Globe to Severely Alter the Enhanced Oil Recovery Market Dynamics

Written by Customer Service on . Posted in Mergers And Acquisitions.

Companies Covered in Enhanced Oil Recovery Market Research Report are Petroleum Development Oman), Petrobras, Cairn Oil & Gas, China National Petroleum Corporation, Husky Energy, Oxy, Ecopetrol, Lukoil, China Petrochemical Corporation, ConocoPhillips, BP, Chevron. Pune, India, Oct. 07, 2021 (GLOBE NEWSWIRE) — The global enhanced oil recovery market size is projected to reach USD 20.06 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. Increasing requirement for advanced oil recovery technologies around the world is expected to be the key growth driver for this market, as per the new Fortune Business Insights™ report, titled “Enhanced Oil Recovery Market Size, Share & Industry Analysis, By Technology (Thermal Injection, Gas Injection, and Chemical Injection), By Application (Onshore and Offshore), and...

Continue reading

Middlefield Canadian Income PCC – Dividend Announcement

Written by Customer Service on . Posted in Dividend Reports And Estimates.

  Middlefield Canadian Income PCC (the “Company”)Including Middlefield Canadian Income – GBP PC (the “Fund”), a cell of the CompanyRegistered No:  93546Legal Entity Identifier: 2138007ENW3JEJXC8658                         7 October 2021 Dividend Announcement Middlefield Canadian Income PCC is pleased to announce that the board of directors has declared a quarterly dividend of 1.275 pence per Share with respect to Middlefield Canadian Income – GBP PC (the “Fund”). The dividend will be paid gross on Friday, 29 October 2021 to Shareholders of record on Friday, 15 October 2021.  The ex-dividend date is Thursday, 14 October 2021. The Fund trades on the London Stock Exchange under the symbol MCT.  The Fund invests in a broadly diversified, actively managed portfolio of Canadian and U.S. equity income securities.                         ...

Continue reading

Cell Culture Media Market Report 2021-2028 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Revenue, Forecast

Written by Customer Service on . Posted in Mergers And Acquisitions.

The major companies in the global cell culture media report include Thermo Fisher Scientific Corporation, Merck KGaA, CellGenix GmbH, GENERAL ELECTRIC COMPANY, BD, Corning Incorporated, FUJIFILM Holdings Corporation, Lonza. Pune, India, Oct. 07, 2021 (GLOBE NEWSWIRE) — The global cell culture media market size is projected to experience dynamic growth in the forthcoming years owing to the increasing investments in the biotechnology sector, finds Fortune Business Insights™ in its report, titled “Cell Culture Media Market, 2021-2028”. A cell culture media is a solid, liquid, or semisolid media that is made up of several contents and nutrients to stimulate the growth, propagation, maintenance, and storage of microorganisms, and other cell lines. There has been significant increase in the investments in biotechnology sector by the...

Continue reading

COMSTOCK RESOURCES, INC. ANNOUNCES THE DIVESTITURE OF BAKKEN SHALE ASSETS

Written by Customer Service on . Posted in Public Companies.

FRISCO, TX, Oct. 07, 2021 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (“Comstock” or the “Company”) (NYSE: CRK) announced today that it has entered into an asset purchase agreement with Northern Oil & Gas, Inc. (“NOG”) to sell its assets in the Bakken shale for $154 million in cash, subject to adjustment and customary closing conditions. The properties being sold include non-operated interests in over 400 producing wells (65.9 net) with recent production of greater than 4,500 net barrels of oil equivalent per day (approximately 65% oil). The sale is expected to close in the fourth quarter and will have an effective date of October 1, 2021. Comstock expects to recognize a pre-tax loss of $130-$140 million on the divestiture. EnergyNet is acting as exclusive advisor to Comstock on the sale.   Comstock...

Continue reading

CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)

Written by Customer Service on . Posted in Public Companies.

Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center. The study is intended to determine the potential synergistic therapeutic efficacy...

Continue reading

CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV

Written by Customer Service on . Posted in Public Companies.

New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the appointments of Christopher Recknor, M.D. as Senior Executive VP of Clinical Operations and Nitya Ray, Ph.D. as the Company’s Chief Operating Officer.   CytoDyn is realigning its management structure to optimize the BLA resubmission process and to advance clinical development potential. The team of Drs. Ray and Recknor will now hire additional...

Continue reading

Brunswick Corporation Schedules Third Quarter Earnings Conference Call October 28

Written by Customer Service on . Posted in Public Companies.

METTAWA, Ill., Oct. 07, 2021 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its third quarter 2021 financial results on Thursday October 28, 2021, before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website at https://ir.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1.  The Company will hold a conference call at 10 a.m. CDT/ 11 a.m. EST, Thursday, October 28, 2021, hosted by David M. Foulkes, chief executive officer, Ryan M. Gwillim, executive vice president and chief financial officer and Brent Dahl, vice president of investor relations.  A copy of the presentation to be used on this call will be available when the results are...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.